ProShares has launched the first exchange-traded funds that offer leveraged and inverse exposure to the biotechnology sector.

The ETFs are listed as Ultra Nasdaq Biotechnology (BIB) and UltraShort Nasdaq Biotechnology (BIS) and seek to provide 200% or -200% of the returns of the Nasdaq Biotechnology Index, during a single day.

Subscribe Now

Access to premium content including in-depth coverage of mutual funds, hedge funds, 401(K)s, 529 plans, and more.

3-Week Free Trial

Insight and analysis into the management, marketing, operations and technology of the asset management industry.